Medical Advocates
Nevirapine (Viramune)
 
Journal Citations:
Switching Therapies

General Reports                        
Switching from PIs to NNRTIs
Switching from Efavirenz to Nevirapine





 
NVP Strategies Main Page   Main New/Newsworthy  Home Page
Last Update:  April 13, 2017
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
           
 

FULL-TEXT ARTICLE
 Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.
 Lee CY, Chang HM, Kunin CM, et al
BMC Infect Dis. 2017 Apr 11;17(1):261
 Paper

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity.
 Patterson P, Socías E, Pryluka D,  et al
J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19794
 Abstract


'TRANxITION 144-week results: switching virologically stable HIV patients from immediate-release nevirapine (NVP IR) to extended-release NVP (XR).
Arastéh K, Drulak M, Guo J
J Int AIDS Soc. 2012 Nov 11;15(6):1834
 Abstract

Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Arasteh K, Ward D, Plettenberg A, et al 
HIV Med. 2011 Dec 4.
Abstract

Evaluation of nevirapine-switch strategies for HIV treatment.
 Gil P, de Górgolas M, Estrada V, Arranz A
HIV Med. 2006 Nov;7(8):537-543.
 Abstract
Switching from PIs to NNRTIs
           
 
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination
or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
 Bommenel T, Launay O, Meynard JL, et al
J Antimicrob Chemother. 2011 Jun 1
 Abstract

Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens:
a meta-analysis of randomized controlled trials.
 Ena J, Leach A, Nguyen P, et al 
HIV Med. 2008 Jul 21.
Abstract
 
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful
first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing
efavirenz, nevirapine, or abacavir.
 Abgrall S, Yeni PG, Bouchaud O, et al
Clin Infect Dis. 2007 Jan 1;44(1):120-7.
 Abstract
 
A randomized controlled trial investigating the efficacy and safety of switching from
a protease inhibitor to nevirapine in patients with undetectable viral load.
 Arranz Caso JA, Lopez JC, 
HIV Med. 2005 Sep;6(5):353-9.
Abstract
 
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy
for the management of dyslipidaemia.
 Calza L, Manfredi R, Colangeli V, et al 
AIDS. 2005 Jul 1;19(10):1051-8. R
 Abstract
 
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz
or nevirapine.
 Fisac C, Fumero E, Crespo M, et al
AIDS. 2005 Jun 10;19(9):917-925
 Abstract
 
Serum adiponectin and metabolic parameters in HIV-1-infected patients after
substitution of nevirapine for protease inhibitors.
 Petit JM, Duong M, Masson D, et al
Eur J Clin Invest. 2004 Aug;34(8):569-75
 Abstract
 
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients
with Human Immunodeficiency Virus Infection.
Martinez E, Arnaiz JA, Podzamczer D, et al.
N Engl J Med. 2003 Sep 11;349(11):1036-1046.
 Abstract
 An Interview  with José M. Gatell, MD, PhD, on the NEFA trial data reported in the
September 11 2003, New England Journal of Medicine]

Virological, immunological, and clinical impact of switching from protease inhibitors to
nevirapine or to efavirenz in patients with human immunodeficiency virus infection and
long-lasting viral suppression.
Negredo E, Cruz L, Paredes R, Ruiz Let al.
Clin Infect Dis 2002 Feb 15;34(4):504-10
Abstract
 

  
Switching from Efavirenz to Nevirapine
           
 
Switch from efavirenz to nevirapine, with full dose after one week: efficacy, safety and pharmacokinetics.
 Curran A, Crespo M, van den Eynde E, et al
 J Int AIDS Soc. 2012 Nov 11;15(6):18346.
Abstract

Nevirapine vs efavirenz in virologically suppressed patients: differences in lipoprotein subclasses and inflammatory biomarkers.
 Estrada V, Gómez-Garre M, Santos J, et al
J Int AIDS Soc. 2012 Nov 11;15(6):18151
 Abstract

Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
 Mehta U, Maartens G.
Lancet Infect Dis. 2007 Nov;7(11):733-8.
 Abstract
 
Efavirenz to Nevirapine Switch in HIV-1-Infected Patients with Dyslipidemia: A Randomized,
Controlled Study.
 Parienti JJ, Massari V, Rey D, et al 
Clin Infect Dis. 2007 Jul 15;45(2):263-6.
Abstract

Switch from efavirenz to nevirapine associated with resolution of efavirenz-related
neuropsychiatric adverse events and improvement in lipid profiles.
 Ward DJ, Curtin JM.
AIDS Patient Care STDS. 2006 Aug;20(8):542-8.
 Abstract

 
NVP Strategies Main Page   Main New/Newsworthy  Home Page

Nevirapine Journal Data
 Switching Therapies